JP2017513470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513470A5 JP2017513470A5 JP2016561659A JP2016561659A JP2017513470A5 JP 2017513470 A5 JP2017513470 A5 JP 2017513470A5 JP 2016561659 A JP2016561659 A JP 2016561659A JP 2016561659 A JP2016561659 A JP 2016561659A JP 2017513470 A5 JP2017513470 A5 JP 2017513470A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cancer
- cells
- host cell
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- -1 CE7 Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- 108091006106 transcriptional activators Proteins 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100032831 Protein ITPRID2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977751P | 2014-04-10 | 2014-04-10 | |
| US61/977,751 | 2014-04-10 | ||
| US201461986479P | 2014-04-30 | 2014-04-30 | |
| US61/986,479 | 2014-04-30 | ||
| US201462058973P | 2014-10-02 | 2014-10-02 | |
| US62/058,973 | 2014-10-02 | ||
| US201462088363P | 2014-12-05 | 2014-12-05 | |
| US62/088,363 | 2014-12-05 | ||
| US201462089730P | 2014-12-09 | 2014-12-09 | |
| US62/089,730 | 2014-12-09 | ||
| US201462090845P | 2014-12-11 | 2014-12-11 | |
| US62/090,845 | 2014-12-11 | ||
| PCT/US2015/024947 WO2015157432A1 (en) | 2014-04-10 | 2015-04-08 | Drug related transgene expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155809A Division JP7093385B2 (ja) | 2014-04-10 | 2020-09-16 | 薬物制御による導入遺伝子の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513470A JP2017513470A (ja) | 2017-06-01 |
| JP2017513470A5 true JP2017513470A5 (OSRAM) | 2018-05-24 |
| JP6765968B2 JP6765968B2 (ja) | 2020-10-07 |
Family
ID=54288361
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2016561659A Active JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
| JP2020155809A Active JP7093385B2 (ja) | 2014-04-10 | 2020-09-16 | 薬物制御による導入遺伝子の発現 |
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
| JP2020155809A Active JP7093385B2 (ja) | 2014-04-10 | 2020-09-16 | 薬物制御による導入遺伝子の発現 |
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (12) | US10266592B2 (OSRAM) |
| EP (8) | EP3129053A4 (OSRAM) |
| JP (12) | JP6772068B2 (OSRAM) |
| KR (8) | KR102387243B1 (OSRAM) |
| CN (7) | CN113528581A (OSRAM) |
| AU (8) | AU2015243882C1 (OSRAM) |
| BR (3) | BR112016023517A2 (OSRAM) |
| CA (4) | CA2945303C (OSRAM) |
| ES (2) | ES2880932T3 (OSRAM) |
| IL (5) | IL248243B2 (OSRAM) |
| MX (6) | MX2016013158A (OSRAM) |
| MY (4) | MY192522A (OSRAM) |
| NZ (3) | NZ725079A (OSRAM) |
| PH (4) | PH12016502010B1 (OSRAM) |
| RU (5) | RU2752275C2 (OSRAM) |
| SA (1) | SA516380056B1 (OSRAM) |
| SG (8) | SG10201808825XA (OSRAM) |
| WO (5) | WO2015157432A1 (OSRAM) |
| ZA (3) | ZA201607061B (OSRAM) |
Families Citing this family (203)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100548667C (zh) * | 2003-01-20 | 2009-10-14 | 日本瑞翁株式会社 | 层合件及其制造方法 |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| PL3071223T3 (pl) * | 2013-11-21 | 2021-08-16 | Autolus Limited | Komórka |
| IL248243B2 (en) * | 2014-04-10 | 2024-04-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Defined composition gene modified t-cell products |
| MA51794A (fr) | 2014-04-23 | 2020-05-06 | Juno Therapeutics Inc | Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive |
| GB2540694A (en) | 2014-04-29 | 2017-01-25 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies |
| EP3932950A1 (en) | 2014-10-20 | 2022-01-05 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| KR20170075013A (ko) | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| ES2987087T3 (es) | 2014-12-03 | 2024-11-13 | Juno Therapeutics Inc | Métodos y composiciones para terapia celular adoptiva |
| CN113429485A (zh) | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的抗体及其用途 |
| PT3240805T (pt) | 2014-12-15 | 2025-01-28 | Univ California | Recetor de antigénio quimérico de porta ou biespecífico responsivo a cd19 e cd20 |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| EP3261656B1 (en) * | 2015-02-24 | 2020-08-19 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| KR102678631B1 (ko) | 2015-02-27 | 2024-06-28 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| US10253086B2 (en) * | 2015-04-08 | 2019-04-09 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| WO2016210293A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| WO2017027291A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| EP3352798B1 (en) * | 2015-09-22 | 2025-11-19 | Julius-Maximilians-Universität Würzburg | A method for high level and stable gene transfer in lymphocytes |
| KR20180056770A (ko) | 2015-10-06 | 2018-05-29 | 시티 오브 호프 | Psca로 표적화된 키메라 항원 수용체 |
| WO2017070709A1 (en) * | 2015-10-23 | 2017-04-27 | The Regents Of The University Of Colorado A Body Corporate | Prognosis and treatment of squamous cell carcinomas |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| DK3380620T3 (da) * | 2015-11-23 | 2024-09-23 | Novartis Ag | Optimerede lentivirale transfervektorer og anvendelse heraf |
| WO2017101749A1 (en) * | 2015-12-14 | 2017-06-22 | Wu Sareina Chiung-Yuan | Transposon system, kit comprising the same, and uses thereof |
| US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| EP3430549A1 (en) | 2016-03-16 | 2019-01-23 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US12060394B2 (en) | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| KR20230042703A (ko) * | 2016-06-07 | 2023-03-29 | 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 | Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포 |
| CN110191898B (zh) * | 2016-06-08 | 2024-05-10 | 英特瑞克斯顿股份有限公司 | Cd33特异性嵌合抗原受体 |
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| ES2939646T3 (es) | 2016-10-13 | 2023-04-25 | Juno Therapeutics Inc | Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano |
| WO2018075941A1 (en) * | 2016-10-21 | 2018-04-26 | Washington University | Ap4 and methods of promoting t cell activation |
| CN110234327A (zh) * | 2016-11-30 | 2019-09-13 | 英特拉克森公司 | 类固醇施用和免疫疗法 |
| WO2018102785A2 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| MX2019006631A (es) * | 2016-12-12 | 2019-11-12 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. |
| CN106800601B (zh) * | 2017-01-19 | 2021-04-06 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| CA3050085A1 (en) * | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| BR112019017767A2 (pt) | 2017-02-27 | 2020-04-07 | Juno Therapeutics Inc | composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular |
| EP3589295B1 (en) | 2017-02-28 | 2024-09-11 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| IL292352B2 (en) | 2017-03-14 | 2024-03-01 | Juno Therapeutics Inc | Methods for cryogenic storage |
| CN106963945A (zh) * | 2017-03-27 | 2017-07-21 | 山东兴瑞生物科技有限公司 | 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗 |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
| EP3624814A4 (en) * | 2017-05-17 | 2021-02-24 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | GENERATION OF SYNTHETIC INDUCTIBLE PROMOTERS BY ACTIVATION OF MAMMAL T-LYMPHOCYTES (SYN + PRO) TO IMPROVE TREATMENT OF T-LYMPHOCYTES |
| WO2018218038A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| KR102460173B1 (ko) * | 2017-05-26 | 2022-10-31 | 주식회사 지씨셀 | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 |
| CN118662614A (zh) | 2017-06-02 | 2024-09-20 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| WO2018237022A1 (en) | 2017-06-21 | 2018-12-27 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| CN107335054B (zh) * | 2017-06-30 | 2021-01-15 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
| JP6817492B2 (ja) | 2017-08-07 | 2021-01-20 | エヌビーイー セラピューティクス アクチェン ゲゼルシャフト | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 |
| CA3072569A1 (en) * | 2017-08-11 | 2019-02-14 | Tribiotica Llc | Methods for generating epitopes for binding to recognition molecules by templated assembly |
| US11643468B2 (en) * | 2017-08-23 | 2023-05-09 | Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-Gemeinschaft | Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders |
| AU2018339528A1 (en) * | 2017-09-26 | 2020-04-16 | Longwood University | PD1-specific chimeric antigen receptor as an immunotherapy |
| CN107759700A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd19抗原的转基因t细胞及其制备方法与应用 |
| WO2019079486A1 (en) | 2017-10-18 | 2019-04-25 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| PT3704230T (pt) | 2017-11-01 | 2024-11-19 | Juno Therapeutics Inc | Processo para gerar composições terapêuticas de células modificadas |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| ES3003809T3 (en) | 2017-11-01 | 2025-03-11 | Juno Therapeutics Inc | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| EP3703688A2 (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| CN120608077A (zh) | 2017-11-10 | 2025-09-09 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| CA3082570A1 (en) | 2017-11-14 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Il-36 secreting immunoresponsive cells and uses thereof |
| EP3720480A2 (en) | 2017-12-08 | 2020-10-14 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CA3086832A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院（血液学研究所） | 高效率血细胞重编程同时实现基因编辑的方法 |
| MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
| CN108383914A (zh) | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| JP2021515576A (ja) * | 2018-03-16 | 2021-06-24 | イミュソフト コーポレーション | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| ES3035911T3 (en) | 2018-04-19 | 2025-09-11 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| KR20210018838A (ko) | 2018-05-15 | 2021-02-18 | 카르스젠 테라퓨틱스 컴퍼니, 리미티드 | 유전자 조작된 세포 및 응용 |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| MX2021001523A (es) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Procesos para generar células modificadas y composiciones de las mismas. |
| WO2020037142A1 (en) | 2018-08-17 | 2020-02-20 | Yale University | Compositions and methods for high-throughput activation screening to boost t cell effector function |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| WO2020044239A1 (en) * | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN113039206A (zh) * | 2018-08-31 | 2021-06-25 | 西雅图儿童医院（Dba西雅图儿童研究所） | 包含b7h3嵌合抗原受体的方法和组合物 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| BR112021007334A2 (pt) * | 2018-10-19 | 2021-08-03 | Cartexell Inc. | anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| TW202031894A (zh) | 2018-11-01 | 2020-09-01 | 中國大陸商亘喜生物科技（上海）有限公司 | 用於t細胞工程之組合物及方法 |
| CA3120085A1 (en) | 2018-11-14 | 2020-05-22 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed t-cells |
| EP3880238A1 (en) * | 2018-11-16 | 2021-09-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| EP3886876A1 (en) * | 2018-11-30 | 2021-10-06 | Celularity Inc. | Placenta-derived allogeneic car-t cells and uses thereof |
| PT3886894T (pt) * | 2018-11-30 | 2024-05-02 | Juno Therapeutics Inc | Métodos para dosagem e tratamento de malignidades de células b em terapia celular adotiva |
| BR112021010354A2 (pt) * | 2018-11-30 | 2021-11-03 | Juno Therapeutics Inc | Métodos para o tratamento usando terapia celular adotiva |
| EP3898993A1 (en) * | 2018-12-20 | 2021-10-27 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020191172A1 (en) * | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| US20200308248A1 (en) * | 2019-03-26 | 2020-10-01 | ST Phi Therapeutics | Chimeric Natural Killer Cell Receptors and Method of Using Thereof |
| WO2020210023A1 (en) * | 2019-04-08 | 2020-10-15 | Russell Biotech, Inc. | Improved manufacturing procedures for cell based therapies |
| CN109994176A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含样本类型信息管理模块的精准用药智能报告系统 |
| CN109979545A (zh) * | 2019-04-16 | 2019-07-05 | 北京中佰耀因医药科技有限公司 | 一种含样本状态信息管理模块的精准用药智能报告系统 |
| CN109994156A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含报告模板信息管理模块的精准用药智能报告系统 |
| CN109994180A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含基因位点信息管理模块的精准用药智能报告系统 |
| CN110010200A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基因身份识别系统 |
| CN110010222A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基于精准用药知识库的基因身份识别系统 |
| CN109872792A (zh) * | 2019-04-16 | 2019-06-11 | 北京中佰耀因医药科技有限公司 | 一种用于指导精准用药的基因检测智能报告系统 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| JP7612617B2 (ja) * | 2019-06-17 | 2025-01-14 | レノヴァロ バイオファーマ インコーポレイテッド | 細胞性免疫及び体液性免疫を誘導するための同種異系ｔ細胞ベースのｈｉｖワクチン |
| AU2020295715A1 (en) * | 2019-06-19 | 2022-02-17 | Julius-Maximilians-Universität Würzburg | Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| CN110608991B (zh) * | 2019-09-09 | 2022-04-29 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法 |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MY209360A (en) | 2019-10-31 | 2025-07-03 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| KR20220142484A (ko) | 2020-02-14 | 2022-10-21 | 조운스 테라퓨틱스, 인크. | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
| MX2022011673A (es) | 2020-03-20 | 2022-12-13 | Lyell Immunopharma Inc | Nuevos marcadores de superficie celular recombinantes. |
| JP7564888B2 (ja) | 2020-05-01 | 2024-10-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物 |
| GB202007169D0 (en) * | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| US20230212257A1 (en) * | 2020-06-08 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-cd171 chimeric antigen receptors |
| CN115701999A (zh) * | 2020-07-09 | 2023-02-14 | 南京传奇生物科技有限公司 | 用白介素-36工程化γδT细胞用于免疫疗法 |
| JP2023535371A (ja) | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法 |
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| CA3202218A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4277639A4 (en) * | 2021-01-15 | 2025-03-05 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | HYBRID AND TRUNCATED IMMUNE CELL PROTEINS |
| EP4298120A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2023025208A1 (zh) * | 2021-08-24 | 2023-03-02 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| CA3232968A1 (en) | 2021-10-14 | 2023-04-20 | Jasper Williams | Immune cells having co-expressed shrnas and logic gate systems |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023173137A1 (en) * | 2022-03-11 | 2023-09-14 | Yale University | Compositions and methods for efficient and stable genetic modification of eukaryotic cells |
| MX2024011279A (es) | 2022-03-17 | 2024-09-25 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos. |
| CA3254506A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH -2 |
| EP4504243A1 (en) * | 2022-04-01 | 2025-02-12 | Miltenyi Biotec B.V. & Co. KG | A system for drug-inducible expression of a polynucleotide |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| CA3250304A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | IL-15 Bound to a Membrane, CD8 Polypeptides, Cells, Compositions and Related Methods of Use |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
| EP4532701A1 (en) * | 2022-05-27 | 2025-04-09 | Autolus Limited | Method |
| AR129552A1 (es) * | 2022-06-10 | 2024-09-04 | Joint Stock Company Biocad | Ácido nucleico con actividad promotora y uso del mismo |
| WO2024006702A1 (en) * | 2022-06-27 | 2024-01-04 | Foundation Medicine, Inc. | Methods and systems for predicting genotypic calls from whole-slide images |
| AU2023298558A1 (en) | 2022-07-01 | 2024-12-19 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2024129984A1 (en) * | 2022-12-15 | 2024-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Homology-independent targeted dna insertion in human t cells |
| EP4638486A2 (en) * | 2022-12-20 | 2025-10-29 | Abata Therapeutics, Inc. | Cell therapies for type 1 diabetes |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118359729A (zh) * | 2023-01-19 | 2024-07-19 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
| US20240290628A1 (en) * | 2023-02-24 | 2024-08-29 | American Air Liquide, Inc. | Etching method using oxygen-containing hydrofluorocarbon |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN116844685B (zh) * | 2023-07-03 | 2024-04-12 | 广州默锐医药科技有限公司 | 一种免疫治疗效果评估方法、装置、电子设备及存储介质 |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025207642A1 (en) * | 2024-03-25 | 2025-10-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Cxcr3 isoforms to improve recombinant receptor trafficking |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| WO1994000143A1 (en) | 1992-06-01 | 1994-01-06 | New England Medical Center Hospitals, Inc. | Blocking intercellular interactions with cd43 chimeric molecules |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20040037816A1 (en) | 1999-04-15 | 2004-02-26 | Monash University | Graft acceptance through manipulation of thymic regeneration |
| US6912492B1 (en) * | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| JP4045713B2 (ja) | 2000-01-31 | 2008-02-13 | 松下電器産業株式会社 | 自動機用溶接機 |
| GB0015119D0 (en) * | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| WO2002002783A2 (en) | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Expression vectors |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) * | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| AU2002303903A1 (en) | 2001-05-31 | 2002-12-09 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| US20050004017A1 (en) | 2001-09-18 | 2005-01-06 | Yuval Reiss | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| EP1572939A4 (en) | 2002-04-11 | 2006-08-30 | Amgen Inc | HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF |
| WO2004029284A2 (en) | 2002-09-30 | 2004-04-08 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| CN1809277A (zh) * | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | 先于胸腺再活化的移植物耐受 |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| RU2397249C2 (ru) | 2003-07-21 | 2010-08-20 | Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа | СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ |
| JP2007535906A (ja) * | 2003-10-24 | 2007-12-13 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 直交遺伝子スイッチ |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) * | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| DE202005002921U1 (de) | 2005-02-23 | 2005-04-21 | Magcode Ag | Verbindungssystem, insbesondere elektrisches Verbindungssystem |
| US20070020237A1 (en) | 2005-06-01 | 2007-01-25 | Biotech Institute For International Innovation, Inc. | Glucose inducible insulin expression and methods of treating diabetes |
| WO2007073499A2 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Inc. | Epha2 bite molecules and uses thereof |
| BRPI0711207A2 (pt) | 2006-05-22 | 2011-03-22 | Hiprocell Llc | vetor alvo para intregação em sìtios-especificos, método de sìtio-especìfico que integra um polinucleotìdeo codificando uma proteina de interesse em um genoma de uma célula eucariótia, célula eucariótica isolada , kit para uso no sìtio-especìfico que integra um polinucleotideo dentro de um genoma de uma celula in vitro e kit para uso em produzir uma proteìna em célula |
| US8148129B2 (en) | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) * | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| US20100183516A1 (en) | 2007-07-25 | 2010-07-22 | Markus Ribbert | Self coupling recombinant antibody fusion proteins |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| DK2279253T3 (en) * | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| ES2961498T3 (es) | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
| DK2346995T3 (en) | 2008-09-26 | 2019-02-11 | Tocagen Inc | GENETERIVE VECTORS AND CYTOSINDEAMINASES |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| US20100332417A1 (en) * | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US9873035B2 (en) * | 2009-07-09 | 2018-01-23 | Cfph, Llc | Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| SI2496698T1 (sl) * | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| ES2656414T3 (es) | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012099973A2 (en) * | 2011-01-18 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| SG193591A1 (en) | 2011-03-23 | 2013-10-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| JP2014514927A (ja) | 2011-04-13 | 2014-06-26 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| JP6246711B2 (ja) * | 2011-06-22 | 2017-12-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去 |
| CA2851795C (en) | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
| ITRM20120058A1 (it) * | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| IN2014DN07414A (OSRAM) * | 2012-02-22 | 2015-04-24 | Univ Pennsylvania | |
| JP6359520B2 (ja) * | 2012-04-11 | 2018-07-18 | アメリカ合衆国 | Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体 |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| BR112014030007A2 (pt) | 2012-05-30 | 2017-06-27 | Baylor College Medicine | minivetores superenrolados como uma ferramenta para reparação, alteração e substituição de dna |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| CN104350709B (zh) | 2012-06-01 | 2018-03-13 | 日本电气株式会社 | 交换机系统、线路卡、交换卡、fdb学习方法及fdb学习调停方法 |
| RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
| WO2014039044A1 (en) * | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9598489B2 (en) * | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| JP6409009B2 (ja) * | 2013-03-07 | 2018-10-17 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | がんにおけるｃｄ１３８の標的化 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| KR102238226B1 (ko) * | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| RU2733652C2 (ru) | 2013-10-31 | 2020-10-06 | Фред Хатчинсон Кэнсер Рисерч Сентер | МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ |
| PL3071223T3 (pl) | 2013-11-21 | 2021-08-16 | Autolus Limited | Komórka |
| JP2017504598A (ja) | 2013-12-20 | 2017-02-09 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化インクレチン受容体リガンドヒト免疫グロブリンｆｃ−領域融合ポリペプチド |
| JP2017504601A (ja) | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CA2931979A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding properties |
| AU2015218239B2 (en) | 2014-02-14 | 2019-01-31 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| IL248243B2 (en) | 2014-04-10 | 2024-04-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Defined composition gene modified t-cell products |
| KR102110187B1 (ko) | 2014-05-14 | 2020-05-14 | 카르스젠 테라퓨틱스 리미티드 | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 |
| EP3149044B1 (en) | 2014-06-02 | 2020-10-21 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting cd-19 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| MX389823B (es) | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| KR102526538B1 (ko) | 2015-06-10 | 2023-04-28 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| ES2854731T3 (es) | 2015-06-12 | 2021-09-22 | Lentigen Tech Inc | Procedimiento para tratar cáncer con células T modificadas genéticamente |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| ES2879700T3 (es) | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| EP3518972B1 (en) | 2016-09-28 | 2024-12-25 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| ES2925644T3 (es) | 2016-10-04 | 2022-10-19 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células modificadas genéticamente |
| MX2019006631A (es) | 2016-12-12 | 2019-11-12 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| KR20210074274A (ko) | 2018-08-06 | 2021-06-21 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물 |
| US10714296B2 (en) | 2018-12-12 | 2020-07-14 | Axcelis Technologies, Inc. | Ion source with tailored extraction shape |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2015
- 2015-04-08 IL IL248243A patent/IL248243B2/en unknown
- 2015-04-08 AU AU2015243882A patent/AU2015243882C1/en not_active Ceased
- 2015-04-08 MX MX2016013158A patent/MX2016013158A/es unknown
- 2015-04-08 PH PH1/2016/502010A patent/PH12016502010B1/en unknown
- 2015-04-08 US US15/302,415 patent/US10266592B2/en active Active
- 2015-04-08 SG SG10201808825XA patent/SG10201808825XA/en unknown
- 2015-04-08 SG SG10201808819XA patent/SG10201808819XA/en unknown
- 2015-04-08 WO PCT/US2015/024947 patent/WO2015157432A1/en not_active Ceased
- 2015-04-08 EP EP15776211.3A patent/EP3129053A4/en not_active Withdrawn
- 2015-04-08 PH PH1/2016/502009A patent/PH12016502009B1/en unknown
- 2015-04-08 EP EP15777065.2A patent/EP3129399B1/en active Active
- 2015-04-08 JP JP2016561722A patent/JP6772068B2/ja active Active
- 2015-04-08 BR BR112016023517A patent/BR112016023517A2/pt not_active Application Discontinuation
- 2015-04-08 IL IL248238A patent/IL248238B2/en unknown
- 2015-04-08 SG SG11201608395PA patent/SG11201608395PA/en unknown
- 2015-04-08 RU RU2016143381A patent/RU2752275C2/ru active
- 2015-04-08 JP JP2016561635A patent/JP6765967B2/ja active Active
- 2015-04-08 EP EP15776745.0A patent/EP3129405B1/en active Active
- 2015-04-08 KR KR1020167031068A patent/KR102387243B1/ko active Active
- 2015-04-08 KR KR1020237007831A patent/KR102730216B1/ko active Active
- 2015-04-08 CN CN202110842538.7A patent/CN113528581A/zh active Pending
- 2015-04-08 RU RU2016143384A patent/RU2729112C2/ru active
- 2015-04-08 AU AU2015243922A patent/AU2015243922B2/en active Active
- 2015-04-08 CN CN201580029752.3A patent/CN106535934A/zh active Pending
- 2015-04-08 RU RU2016143388A patent/RU2751920C2/ru active
- 2015-04-08 US US15/302,449 patent/US20170029774A1/en not_active Abandoned
- 2015-04-08 WO PCT/US2015/024866 patent/WO2015157384A1/en not_active Ceased
- 2015-04-08 ES ES15777065T patent/ES2880932T3/es active Active
- 2015-04-08 SG SG11201608392WA patent/SG11201608392WA/en unknown
- 2015-04-08 WO PCT/US2015/024868 patent/WO2015157386A1/en not_active Ceased
- 2015-04-08 WO PCT/US2015/024882 patent/WO2015157391A1/en not_active Ceased
- 2015-04-08 US US15/302,426 patent/US20170015746A1/en not_active Abandoned
- 2015-04-08 EP EP22151326.0A patent/EP4056201A1/en not_active Withdrawn
- 2015-04-08 RU RU2016143385A patent/RU2751921C2/ru active
- 2015-04-08 MX MX2016013160A patent/MX387465B/es unknown
- 2015-04-08 MX MX2016013149A patent/MX2016013149A/es unknown
- 2015-04-08 KR KR1020167031069A patent/KR20160144431A/ko not_active Abandoned
- 2015-04-08 MY MYPI2016703722A patent/MY192522A/en unknown
- 2015-04-08 KR KR1020227011931A patent/KR102600544B1/ko active Active
- 2015-04-08 JP JP2016561659A patent/JP6765968B2/ja active Active
- 2015-04-08 NZ NZ725079A patent/NZ725079A/en not_active IP Right Cessation
- 2015-04-08 CN CN202110101875.0A patent/CN112877291A/zh active Pending
- 2015-04-08 CN CN201580030056.4A patent/CN106574246A/zh active Pending
- 2015-04-08 MX MX2016013144A patent/MX395574B/es unknown
- 2015-04-08 KR KR1020227038237A patent/KR102618955B1/ko active Active
- 2015-04-08 MY MYPI2016703720A patent/MY186846A/en unknown
- 2015-04-08 JP JP2016561839A patent/JP2017515464A/ja active Pending
- 2015-04-08 EP EP15776501.7A patent/EP3129480A4/en active Pending
- 2015-04-08 CA CA2945303A patent/CA2945303C/en active Active
- 2015-04-08 CA CA2945320A patent/CA2945320A1/en active Pending
- 2015-04-08 KR KR1020167031070A patent/KR102509481B1/ko active Active
- 2015-04-08 NZ NZ725081A patent/NZ725081A/en not_active IP Right Cessation
- 2015-04-08 CN CN201580030814.2A patent/CN106536558A/zh active Pending
- 2015-04-08 CN CN201580030815.7A patent/CN106661570B/zh active Active
- 2015-04-08 JP JP2017504604A patent/JP6788573B6/ja active Active
- 2015-04-08 US US15/302,403 patent/US10865242B2/en active Active
- 2015-04-08 MX MX2016013159A patent/MX389797B/es unknown
- 2015-04-08 WO PCT/US2015/024895 patent/WO2015157399A1/en not_active Ceased
- 2015-04-08 AU AU2015243920A patent/AU2015243920B2/en not_active Ceased
- 2015-04-08 CN CN201580027077.0A patent/CN106573969B/zh active Active
- 2015-04-08 EP EP15777020.7A patent/EP3129471A4/en active Pending
- 2015-04-08 AU AU2015243927A patent/AU2015243927B2/en not_active Ceased
- 2015-04-08 BR BR112016023500-2A patent/BR112016023500B1/pt active IP Right Grant
- 2015-04-08 ES ES15776745T patent/ES2867224T3/es active Active
- 2015-04-08 MY MYPI2016703719A patent/MY185678A/en unknown
- 2015-04-08 SG SG11201608396YA patent/SG11201608396YA/en unknown
- 2015-04-08 EP EP21180797.9A patent/EP3954708A1/en active Pending
- 2015-04-08 SG SG11201608393TA patent/SG11201608393TA/en unknown
- 2015-04-08 KR KR1020167031067A patent/KR102508166B1/ko active Active
- 2015-04-08 RU RU2016143389A patent/RU2016143389A/ru not_active Application Discontinuation
- 2015-04-08 CA CA2945305A patent/CA2945305C/en active Active
- 2015-04-08 IL IL297591A patent/IL297591B2/en unknown
- 2015-04-08 EP EP21175647.3A patent/EP3943507A1/en active Pending
- 2015-04-08 SG SG10201808833XA patent/SG10201808833XA/en unknown
- 2015-04-08 CA CA2945308A patent/CA2945308C/en active Active
- 2015-04-08 SG SG10201808811QA patent/SG10201808811QA/en unknown
- 2015-04-08 NZ NZ73944815A patent/NZ739448A/en not_active IP Right Cessation
- 2015-04-08 PH PH1/2016/502011A patent/PH12016502011B1/en unknown
- 2015-04-08 US US15/302,420 patent/US10611837B2/en active Active
- 2015-04-08 AU AU2015243849A patent/AU2015243849B2/en not_active Ceased
- 2015-04-08 BR BR112016023523A patent/BR112016023523A2/pt not_active Application Discontinuation
- 2015-04-08 MY MYPI2016703721A patent/MY184163A/en unknown
- 2015-04-08 KR KR1020167031064A patent/KR102463529B1/ko active Active
-
2016
- 2016-10-06 IL IL248235A patent/IL248235B/en active IP Right Grant
- 2016-10-06 MX MX2022010807A patent/MX2022010807A/es unknown
- 2016-10-06 IL IL248229A patent/IL248229B2/en unknown
- 2016-10-10 SA SA516380056A patent/SA516380056B1/ar unknown
- 2016-10-10 PH PH12016502012A patent/PH12016502012A1/en unknown
- 2016-10-13 ZA ZA2016/07061A patent/ZA201607061B/en unknown
- 2016-10-13 ZA ZA2016/07053A patent/ZA201607053B/en unknown
- 2016-10-13 ZA ZA2016/07060A patent/ZA201607060B/en unknown
-
2019
- 2019-02-27 US US16/287,074 patent/US11155616B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/794,673 patent/US11414486B2/en active Active
- 2020-06-18 JP JP2020105133A patent/JP7062720B2/ja active Active
- 2020-09-16 JP JP2020155809A patent/JP7093385B2/ja active Active
- 2020-09-16 JP JP2020155429A patent/JP7148580B2/ja active Active
- 2020-09-30 JP JP2020164326A patent/JP7106610B2/ja active Active
- 2020-11-12 US US17/096,138 patent/US12258397B2/en active Active
- 2020-11-13 US US17/097,630 patent/US20210371517A1/en active Pending
-
2021
- 2021-01-04 AU AU2021200007A patent/AU2021200007B2/en not_active Ceased
- 2021-03-17 AU AU2021201679A patent/AU2021201679B2/en not_active Ceased
- 2021-09-10 US US17/472,284 patent/US12202897B2/en active Active
- 2021-11-26 AU AU2021273652A patent/AU2021273652A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069142A patent/JP7542270B2/ja active Active
- 2022-04-21 US US17/660,114 patent/US12503507B2/en active Active
- 2022-07-13 JP JP2022112278A patent/JP7402933B2/ja active Active
- 2022-07-15 US US17/812,848 patent/US12448445B2/en active Active
- 2022-09-22 JP JP2022150928A patent/JP7508516B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513470A5 (OSRAM) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2017515464A5 (OSRAM) | ||
| Han et al. | Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges | |
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| Schönfeld et al. | Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor | |
| Liu et al. | Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy | |
| JP2021019589A5 (OSRAM) | ||
| JP2019500894A5 (OSRAM) | ||
| JP2018529327A5 (OSRAM) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2020500563A5 (OSRAM) | ||
| JP2017513478A5 (OSRAM) | ||
| JP2018522567A5 (OSRAM) | ||
| JP2015527070A5 (OSRAM) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2014512183A5 (OSRAM) | ||
| JP2018522564A5 (OSRAM) | ||
| Turtle | Chimeric antigen receptor modified T cell therapy for B cell malignancies | |
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение |